Business Wire

BELFOR, den globala marknadsledaren inom skadeservice, utökar sin geografiska täckning med SSG Group, Skandinavien

Dela

BELFOR, världens ledande leverantör av skadeservice, och SSG, den skandinaviska marknadsledaren inom skadesanering och restaurering efter skada, har gått samman för att stärka sin kundservice i Danmark, Sverige och Norge.

Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20220622005635/sv/

För att se det här innehållet från mms.businesswire.com måste du ge ditt medgivande sidans topp.

BELFOR, den globala marknadsledaren inom skadeservice, utökar sin geografiska täckning med SSG Group, Skandinavien (Grafik: Business Wire)

BELFOR, nu med mer än 12 500 anställda på 500+ platser över hela världen, täcker hela värdekedjan inom skadeservice. Vi bedömer skadan, genomför första lindrande åtgärder och restaurerar det skadade området.

SSG Group tillhandahåller ett brett utbud av tjänster med fokus på skadeservice och återställande arbete, med 980 anställda på 57 orter i Danmark, Sverige och Norge.

”Med SSG kommer vi utöka vårt redan skickliga och erfarna team med fantastiska människor, öka vår servicekapacitet, och optimera vår responstid för både nationella och internationella kunder”, berättar Elvir Kolak, VD för BELFOR Europe.

”Denna transaktion innebär ett enormt uppsving för våra organisationer i Danmark, Norge och Sverige. Genom att komplettera BELFORs tekniska kompetens till vår tjänsteportfölj öppnar vi nya utvecklingsmöjligheter för våra anställda.”, tillägger Carsten Fensholt, VD för SSG Group.

”Vi är glada att välkomna SSG till vår BELFOR-familj och är glada över att stödja deras framtida tillväxt. SSG består av underbara människor med ett stort kundfokus och är därför en perfekt match för oss! Vi är stolta över att ha dem ombord. Våra tillväxtplaner är ambitiösa och vi letar efter fler fantastiska företag att ansluta sig till BELFOR-familjen – både i Skandinavien och i resten av Europa”, avslutar Sheldon Yellen, den globala VD:n för BELFOR.

OM BELFOR

BELFOR är världens ledande leverantör av skadeservice. BELFOR har över 40 års erfarenhet som täcker hela värdekedjan från skadebedömning, restaurering och renoveringstjänster. Detta gör oss till en föredragen partner för såväl försäkringsbranschen som för kommersiella och privata kunder.

Med SSG kommer BELFOR att ha mer än 12 500 anställda och 500+ platser i 57 länder. Redo att hjälpa kunder med små, stora och tekniskt komplexa förluster 24/7, 365 dagar om året.

www.belfor.com

För att se det här innehållet från cts.businesswire.com måste du ge ditt medgivande sidans topp.

Contact information

Cornelia Meyer von Bremen
Tel: +49 (0) 203 - 7 56 40-300
cornelia.meyervonbremen@belfor.com

Om

Business Wire
Business Wire



Följ Business Wire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum